Fusion Pharmaceuticals Inc (DELISTED) (FUSN:DL)
21.55
0.00 (0.00%)
USD |
NASDAQ |
Jun 04, 16:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 1.833B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 339.8% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 713.16 |
Price to Book Value | 7.580 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | -- |
Profile
Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company’s focus is on the development of next-generation radiopharmaceuticals as precision medicines for hard-to-treat cancers. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others. |
URL | https://www.fusionpharma.com |
Investor Relations URL | https://ir.fusionpharma.com/ |
HQ State/Province | Ontario |
Sector | |
Industry | |
Equity Style | Small Cap/Value |
Next Earnings Release | Aug. 08, 2024 (est.) |
Last Earnings Release | May. 07, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company’s focus is on the development of next-generation radiopharmaceuticals as precision medicines for hard-to-treat cancers. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others. |
URL | https://www.fusionpharma.com |
Investor Relations URL | https://ir.fusionpharma.com/ |
HQ State/Province | Ontario |
Sector | |
Industry | |
Equity Style | Small Cap/Value |
Next Earnings Release | Aug. 08, 2024 (est.) |
Last Earnings Release | May. 07, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |